Previous close | 23.86 |
Open | 24.14 |
Bid | 24.01 x 100 |
Ask | 24.07 x 600 |
Day's range | 23.92 - 24.48 |
52-week range | 22.01 - 33.71 |
Volume | |
Avg. volume | 2,082,939 |
Market cap | 4.07B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 7.16 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2024.
Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of ALKS 2680 compared to placebo in patients with narcolepsy type 1 (NT1). ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy, a chronic, neurological disorder characterized by excessive daytime sleepiness. NT1 is associated with an absence or significant deficiency